Company Team Projects Media Contact

An innovative therapeutic approach to bacterial infection

Combioxin develops innovative anti-virulence treatments for serious bacterial infections, including those caused by antibiotic-resistant strains. The lead candidate, CAL02, is a first-in-class, clinical-stage non-antibiotic liposomal drug that neutralizes bacterial toxins, protects against infection severity and complications, and improves antibiotic efficacy.



Combioxin to present CAL02's clinical data at the FDA's Workshop on the Development of Non-Traditional Therapies for Bacterial Infections, at FDA's White Oak campus on Aug 21-22, 2018

Combioxin selected for oral presentation on the results of the first CAL02 clinical trial at the ESICM Annual Congress in Paris on Oct 24, 2018

Positive topline results from CAL02 FIM trial in the treatment of severe pneumonia - 17/04/2018